No Data
No Data
Alumis And ACELYRIN's Merger Marks A New Era For Late-Stage Biopharma Advancements
Alumis and Acelyrin Sign Merger Agreement
Wells Fargo Maintains Acelyrin(SLRN.US) With Buy Rating
Piper Sandler Sticks to Their Buy Rating for ACELYRIN, INC. (SLRN)
ACELYRIN, INC. (SLRN) Receives a Buy From Wells Fargo
Shareholder Alert: Ademi & Fruchter LLP Investigates Whether ACELYRIN, INC. Is Obtaining a Fair Price for Its Public Shareholders
Unlock the Full List